FDA approves Amgen drug for prevention of migraines

Leslie Hanson
May 18, 2018

US regulators Thursday approved the first drug created to prevent chronic migraines. The drug named, Aimovig is given on a monthly basis by self-injections and will be priced at Dollars 6,900 annually or USD 575 monthly. The price applies to both a 70 milligram and a 140 mg dose. Kristen Davis, Amgen's spokesperson discounts, and rebates will depend on negotiations with health plans. It's the first in an entirely new class of drugs created to block the activity of a specific peptide known to activate migraines that has been cleared for public use by the agency.

The price as expected by some Wall Street experts was going to be Dollars 10,000 a year. It has called for Amgen to reconsider its strategy of setting a high list price for new drugs and then lowering the cost of health plans through hefty rebates.

Wall Street analysts expected the pricing of the Amgen drug to set the tone for that new class of drugs.

The high cost of drugs was addressed by President Trump last week.

Companies including Teva Pharmaceuticals, Eli Lilly and Alder Biopharmaceuticals are developing similar treatments.


The most common side effects reported by patients in the trials were injection site reactions and constipation. The drug is a pretty large step for those who suffer from migraines, as most pre-existing medications do not prevent all attacks, but can make them less severe and reduce their frequency.

Current migraine treatments are mostly repurposed generic drugs including anti-depressants and hypertension medicines.

Analysts, on average, have forecast annual Aimovig sales of almost $1 billion by 2022, according to Thomson Reuters I/B/E/S.

Express Scripts, is a largest USA manager of prescription benefits.

"Aimovig provides patients with a novel option for reducing the number of days with migraine", said Eric Bastings, deputy director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER